By apyxmedical In 2021 Shareholder News, J-Plasma, RenuvionPosted June 3, 2021APYX MEDICAL CORPORATION TO PARTICIPATE IN THE JMP SECURITIES LIFE SCIENCES CONFERENCE READ MORE
By apyxmedical In 2021 Shareholder News, J-Plasma, RenuvionPosted June 1, 2021APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF RENUVION IN DERMAL RESURFACING PROCEDURES READ MORE
By apyxmedical In 2021 Shareholder News, J-Plasma, RenuvionPosted May 12, 2021APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND UPDATES FULL YEAR 2021 OUTLOOK READ MORE
By apyxmedical In 2021 Shareholder News, J-Plasma, RenuvionPosted April 12, 2021APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2021 FINANCIAL RESULTS ON MAY 12, 2021 READ MORE
By apyxmedical In 2020 Shareholder News, 2021 Shareholder News, J-Plasma, RenuvionPosted March 31, 2021APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2021 FINANCIAL OUTLOOK READ MORE
By apyxmedical In 2021 Shareholder News, J-Plasma, RenuvionPosted February 1, 2021APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS ON MARCH 31, 2021 READ MORE
By apyxmedical In 2021 Shareholder News, J-Plasma, RenuvionPosted January 13, 2021APYX MEDICAL CORPORATION REPORTS PRELIMINARY FULL YEAR AND FOURTH QUARTER 2020 REVENUE RESULTS READ MORE
By apyxmedical In 2020 Shareholder News, 2021 Shareholder News, J-Plasma, RenuvionPosted January 5, 2021APYX MEDICAL CORPORATION TO PARTICIPATE IN THE ICR CONFERENCE 2021 READ MORE
By apyxmedical In 2020 Shareholder News, Case Study, J-Plasma, RenuvionPosted November 23, 2020APYX MEDICAL CORPORATION ANNOUNCES APPROVAL FROM FDA TO BEGIN PHASE II OF U.S. IDE STUDY READ MORE
By apyxmedical In 2020 Shareholder News, J-Plasma, RenuvionPosted November 9, 2020APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS READ MORE
